Skip to main content

Table 2 Death and Major Adverse Cardiac Event (MACE) by group and viral variant

From: Outcomes of patients with active cancers and pre-existing cardiovascular diseases infected with SARS-CoV-2

  

CVD (-)

CVD ( +)

Cardioonc (-)

Cardioonc ( +)

Total

p-value*

Early SARS-CoV-2

Total cases

217,282

22,137

50,212

737

290,368

 

Death (%)

11.1

22.8

26.2

37.6

14.6

< 0.001

MACE (%)

43.1

46.5

47.3

54.5

44.1

< 0.001

Alpha

Total cases

51,579

9923

8870

324

70,696

 

Death (%)

6.9

19.0

17.3

30.9

10.0

< 0.001

MACE (%)

38.1

41.8

37.1

49.4

38.6

< 0.001

Delta

Total cases

34,064

6440

5682

262

70,696

 

Death (%)

5.5

16.7

13.8

22.5

8.2

< 0.001

MACE (%)

36.2

37.0

33.0

40.8

36.0

< 0.001

Omicron

Total cases

6161

2166

1057

68

9452

 

Death (%)

3.7

14.0

8.9

20.6

6.8

< 0.001

MACE (%)

33.8

34.9

25.5

35.3

33.2

< 0.001

  1. CVD (-) Cardiovascular Disease and SARS-CoV-2 negative, Cardioonc (-) Cardiovascular Disease and Active Cancer and SARS-CoV-2 negative, Cardioonc ( +) Cardiovascular Disease and Active Cancer and SARS-CoV-2 positive, CVD ( +) Cardiovascular Disease and SARS-CoV-2 positive
  2. *Chi-square test with p-values was used to assess the proportions among four different cohorts